l General Information |
Product Name | Aliskiren heMifuMarate |
General description | Aliskiren Hemifumarate is an orally active nonpeptide renin inhibitor with antihypertensive activity. |
Synonym | (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate |
Purity | ≥98.0%(HPLC) | CAS Number | 173334-58-2 |
Formula | C32H55N3O8 | Molecular Weight | 609.804 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or almost white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | ≥50mg/mL |
Water | ≥50mg/mL |
l Biological Information |
Biochem/Physiol Actions | Aliskiren Hemifumarate is an orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (ATI). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure. |
l Packaging & Storage |
Packaging | 100mg; 250mg; 1g |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
